KhoNKerriganJFTongT, et al. Respiratory syncytial virus infection and neurologic abnormalities: retrospective cohort study. J Child Neurol. 2004;19(11):859-864.
2.
SteinRTBontLJZarH, et al. Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis. Pediatr Pulmonol. 2017;52(4):556-569.
3.
ShiTMcAllisterDAO’BrienKL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390:946-958.
4.
CasertaMTO’LearySTMunozFMRalstonSL.Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2023;152:e2023061803.
5.
EisenhutM.Extrapulmonary manifestations of severe respiratory syncytial virus infection: a systematic review. Crit Care. 2006;10(4):R107.
6.
NjokuDBKliegmanRM.Atypical extrapulmonary presentations of severe respiratory syncytial virus infection requiring intensive care. Clin Pediatr (Phila). 1993;32:455-460.
7.
MillichapJJWainwrightMS.Neurological complications of respiratory syncytial virus infection: case series and review of literature. J Child Neurol. 2009;24:1499-1503.
8.
SaravanosGLKingCLDengL, et al. Respiratory syncytial virus: associated neurologic complications in children—a systematic review and aggregated case series. J Pediatr. 2021;239:39-49.
9.
AndradeCAKalergisAMBohmwaldK.Potential neurocognitive symptoms due to respiratory syncytial virus infection. Pathogens. 2021;11(1):47.
10.
HasegawaKStevensonMDMansbachJM, et al. Association between hyponatremia and higher bronchiolitis severity among children in the ICU with bronchiolitis. Hosp Pediatr. 2015;5:385.
11.
SzaboFKLomenickJP.Syndrome of inappropriate antidiuretic hormone secretion in an infant with respiratory syncytial virus bronchiolitis. Clin Pediatr (Phila). 2008;47:840-842.
12.
PiconeSMondìVDi PalmaF, et al. Neonatal encephalopathy and SIADH during RSV infection. Am J Perinatol. 2019;36:106-109.
13.
KawashimaHIoiHUshioM, et al. Cerebrospinal fluid analysis in children with seizures from respiratory syncytial virus infection. Scand J Infect Dis. 2009;41:228-231.
14.
BohmwaldKSotoJAAndrade-ParraC, et al. Lung pathology due to hRSV infection impairs blood–brain barrier permeability enabling astrocyte infection and a long-lasting inflammation in the CNS. Brain Behav Immun. 2021;91(1):159–171.
15.
BrittonPNDaleRCBlythCC, et al. Influenza-associated encephalitis/encephalopathy identified by the Australian Childhood Encephalitis Study 2013-2015. Pediatr Infect Dis J. 2017;36:1021-1026.
16.
KneyberMCJBrandenburgAHDe GrootR, et al. Risk factors for respiratory syncytial virus associated apnoea. Eur J Pediatr. 1998;157:331-335.
17.
LindgrenCGrögaardJ.Reflex apnoea response and inflammatory mediators in infants with respiratory tract infection. Acta Paediatr. 1996;85:798-803.
SimõesEAFBontLManzoniP, et al. Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children. Infect Dis Ther. 2018;7(1):87-120.
20.
ZhuQMcLellanJSKallewaardNL, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017;9(388):eaaj1928.
21.
GriffinMPKhanAAEsserMT, et al. Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob Agents Chemother. 2017;61(3):e01714-e01716.
22.
RobbieGJCristeRDall’acquaWF, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013;57:6147-6153.
23.
Food and Drug Administration. Beyfortus (nirsevimab-alip) product label. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2023.
24.
WillsonDFLandriganCPHornSDSmoutRJ.Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr. 2003;143:142-149.
25.
Carbonell-EstranyXFigueras-AloyJLawBJ; the Infeccio’n Respir-atoria Infantil por Virus Respiratorio Sincitial Study Group, the Pediatric Investigators Collaborative Network onInfections in Canada Study Group. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J. 2004;23(11 suppl):193-201.
